KAPA Kairos Pharma, LTD.

NYSE kairospharma.com


$ 0.87 $ -0.02 (-2 %)    

Friday, 07-Nov-2025 15:58:53 EST
QQQ $ 612.14 $ 1.56 (0.26 %)
DIA $ 470.45 $ 1.64 (0.35 %)
SPY $ 672.31 $ 2.95 (0.44 %)
TLT $ 89.45 $ -0.19 (-0.21 %)
GLD $ 367.77 $ 0.35 (0.1 %)
$ 0.8526
$ 0.88
$ 0.81 x 100
$ 1.10 x 100
$ 0.81 - $ 0.88
$ 0.40 - $ 3.25
109,060
na
14.68M
$ 0.42
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 04-15-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintains $9 price target.

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintains $9 price target.

Core News & Articles

Interim efficacy analysis highlights potential value of combination therapy of ENV-105 and apalutamide following positive safet...

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintains $9 price target.

Core News & Articles

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company dedicated to addressing resistance to current cance...

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintains $9 price target.

Core News & Articles

Interim efficacy analysis highlights potential value of combination therapy of apalutamide and ENV105 following positive safety...

Core News & Articles

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today an...

Core News & Articles

Kairos Pharma (AMEX:KAPA) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.05)...

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintains $9 price target.

 why-is-kairos-pharma-stock-surging-on-tuesday

Kairos Pharma reported strong safety results from a Phase 2 trial of ENV-105 in mCRPC, with no serious toxicities seen in the f...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION